Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2491
    -0.0020 (-0.16%)
     

  • Bitcoin GBP

    51,136.68
    -1,006.57 (-1.93%)
     

  • CMC Crypto 200

    1,383.71
    -12.82 (-0.92%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Shire disposes of diabetic leg ulcer treatment Dermagraft

Reuters - UK Focus

LONDON, Jan 17 (Reuters) - British pharmaceutical firm Shire (Dusseldorf: S7E.DU - news) said on Friday it had agreed to divest Dermagraft, a bio-engineered skin substitute used to treat diabetic foot ulcers, to Organogenesis for no upfront payment.

Shire (LSE: SHP.L - news) acquired Dermagraft in June 2011 through its $750 million purchase of privately held Advanced BioHealing, but the treatment failed to realise its development hopes when a late-stage trial to treat venous leg ulcers disappointed later that year.

The company said on Friday that the prospects for the product had reduced significantly following a recent Medicare ruling on reimbursement.

It said it would receive no upfront payment from Canton, Massachusetts-based Organogenesis for the assets, but it would be entitled to receive up to $300 million cash in total milestone payments if it meets sales targets.

It said it would record a loss on disposal of approximately $650 million in the fourth quarter of 2013, which will be excluded from Non GAAP earnings.